PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.

加利福尼亚州普莱森顿（PLEASANTON），2023年12月7日，单细胞和空间生物学领域的领军者，PRNewswire/-10x Genomics，Inc.（纳斯达克：TXG），今天宣布与美国国立卫生研究院阿尔茨海默病和相关痴呆症校内中心（NIH CARD）合作，建立一个更全面的人脑单细胞图谱，以进一步进行神经科学研究。

Known for complementing a broad range of NIH-funded research that requires harnessing emerging technologies at scale, NIH CARD will use Chromium Single Cell Multiome to profile the epigenome and whole transcriptome across millions of individual cells from ancestrally diverse brain samples..

NIH CARD以补充NIH资助的广泛研究而闻名，这些研究需要大规模利用新兴技术，NIH CARD将使用铬单细胞多组来分析来自祖先不同大脑样本的数百万个单个细胞的表观基因组和整个转录组。。

'Our goal is to provide researchers with a highly detailed genetic map of the damage caused in neurodegenerative disorders,' said Andrew B. Singleton, Ph.D., NIH CARD director. 'The hope is that these maps will help scientists increase their understanding and ultimately develop new and better treatments for these devastating disorders.'.

“我们的目标是为研究人员提供一个高度详细的神经退行性疾病损伤的基因图谱，”美国国立卫生研究院卡片主管安德鲁·辛格尔顿（AndrewB.Singleton）博士说希望这些地图将帮助科学家增加他们的理解，并最终为这些毁灭性疾病开发出新的更好的治疗方法。”。

Researchers will analyze more than 1,000 samples across multiple control and diseased human brain regions — such as the brainstem, hippocampus, striatum and cerebellum — to learn more about the cellular changes and underlying regulatory elements associated with neurodegenerative diseases. NIH CARD scientists aim to produce high-quality, standardized and harmonized datasets that can be integrated with other modalities, like long-read DNA sequencing.

研究人员将分析多个对照和患病人脑区域（如脑干、海马、纹状体和小脑）的1000多个样本，以进一步了解与神经退行性疾病相关的细胞变化和潜在调控因素。NIH CARD科学家的目标是产生高质量，标准化和协调的数据集，这些数据集可以与其他方式（如长读DNA测序）集成。

To date, the team has already processed 400 samples with Chromium Single Cell Multiome and recently acquired Visium CytAssist and Xenium In Situ instruments to explore the use of spatial tools for the multi-region atlas..

迄今为止，该团队已经用铬单细胞多组处理了400个样品，最近获得了Visium CytAssist和Xenium原位仪器，以探索多区域地图集的空间工具的使用。。

'So much of neurodegeneration is a black box, but once you start opening up that black box, you have many new avenues for progress. That's what single cell analysis does; it brings to light the ground truth of the underlying biology at massive scale and high resolution,' said Ben Hindson, Co-founder, President and Chief Scientific Officer at 10x Genomics.

“很多神经退行性疾病都是一个黑匣子，但一旦你开始打开这个黑匣子，你就会有许多新的进步途径。这就是单细胞分析所做的；10x基因组学联合创始人、总裁兼首席科学官本·辛德森（BenHindson）说，它以大规模和高分辨率揭示了潜在生物学的基本真相。

'It's energizing to see our technologies help the research community build an expansive reference set for neuroscience, which could ultimately lead towards developing better ways to prevent, diagnose, treat and one day cure these devastating diseases.'.

“看到我们的技术帮助研究界为神经科学建立了一个广泛的参考集，这令人振奋，最终可能会导致开发更好的方法来预防，诊断，治疗和有一天治愈这些毁灭性疾病。”。

The human brain atlas is intended to serve as a neurodegenerative disease reference set that better captures ancestral diversity to enable the translation of genetic risk to biological consequence. The collaboration is expected to produce high quality, standardized data that will be openly available to the global scientific community..

人脑图谱旨在作为神经退行性疾病参考集，更好地捕捉祖先的多样性，从而将遗传风险转化为生物学后果。预计此次合作将产生高质量的标准化数据，供全球科学界公开使用。。

NIH CARD is a collaborative initiative of the National Institute on Aging (NIA) and National Institute of Neurological Disorders and Stroke. This project is funded by the NIA Intramural Research Program (ZIAAG000545). The content of this news release is solely the responsibility of the authors and does not necessarily represent the official views of the NIH..

NIH CARD是国家老龄化研究所（NIA）和国家神经疾病和中风研究所的合作倡议。该项目由NIA校内研究计划（ZIAAG000545）资助。本新闻稿的内容仅由作者负责，不一定代表NIH的官方观点。。

About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology.

约10x Genomics10x Genomics是一家生命科学技术公司，其产品旨在加速对生物学的掌握并促进人类健康。我们的综合解决方案包括用于单细胞和空间生物学的仪器，耗材和软件，可帮助学术和转化研究人员以及生物制药公司以与生物学复杂性相匹配的分辨率和规模了解生物系统。

Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter)..

我们的产品支持肿瘤学、免疫学、神经科学等领域的突破，推动了强有力的发现，改变了世界对健康和疾病的理解。要了解更多信息，请访问10xgenomics.com或通过LinkedIn或X（Twitter）与我们联系。。

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections.

前瞻性声明本新闻稿包含《1933年证券法》第27A节（修订版）和《1934年证券交易法》第21E节（修订版）所载《1995年私人证券诉讼改革法》含义范围内的前瞻性声明，这些声明受这些条款所设“安全港”的约束。

All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'will,''enable,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'see,' 'estimate,' 'predict,' 'potential,' 'would,' 'likely,' 'seek' or 'continue' or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

除历史事实陈述外，所有陈述都可能是前瞻性陈述。前瞻性陈述通常可以通过使用前瞻性术语来识别，例如“可能”，“可能”，“将”，“启用”，“应该”，“预期”，“计划”，“预期”，“可能”，“打算”，“目标”，“项目”，“沉思”，“相信”，“看到”，“估计”，“预测”，“潜力”，“可能”，“会”，“可能，“seek”或“continue”或这些术语的否定词或其变体或类似术语，但没有这些词并不意味着一个声明不是前瞻性的。

These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding the potential impacts of research conducted using our products. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors.

这些前瞻性声明包括关于10x Genomics，Inc.对使用我们的产品进行的研究的潜在影响的期望的声明。这些陈述基于管理层当前的期望、预测、信念、假设和管理层目前可获得的信息，由于多种因素，实际结果和结果可能与这些陈述存在重大差异。

The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the company's most recently-filed 10-K .

可能影响10倍基因组学的重大风险和不确定性，公司的财务和经营业绩以及导致实际业绩与本新闻稿中的前瞻性声明所示存在重大差异的原因，包括公司最近提交的10-K中“风险因素”和“管理层对财务状况和经营业绩的讨论和分析”标题下的讨论。

Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur.

尽管10x Genomics，Inc.认为前瞻性声明中反映的期望是合理的，但它不能保证这些期望将被证明是正确的，也不能保证前瞻性声明中反映的未来结果、活动水平、绩效以及事件和情况将得以实现或发生。

These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics, Inc. may make. Further, such forward-looking statements may not accurately or fully reflect the potential impact adverse events may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc.

这些前瞻性陈述并未反映10x Genomics，Inc.未来可能进行的任何收购、合并、处置、合资企业或投资的潜在影响。此外，此类前瞻性报表可能无法准确或充分反映不良事件可能对10x Genomics，Inc.的业务、财务状况、经营成果和现金流产生的潜在影响。

The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.

本新闻稿中的前瞻性声明基于10x Genomics，Inc.截至本新闻稿发布之日可获得的信息，10x Genomics，Inc.不承担更新任何前瞻性声明的义务，以反映我们预期的任何变化或任何此类声明所依据的事件、条件或情况的任何变化，除非法律要求。

These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release..

这些前瞻性声明不应被视为代表10x Genomics，Inc.截至本新闻稿发布日期之后的任何日期的观点。。

Disclosure Information10x Genomics, Inc. uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD..

披露信息10x Genomics，Inc.使用向证券交易委员会、我们的网站（www.10xgenomics.com）、新闻稿、公共电话会议、公共网络广播和我们的社交媒体账户提交的文件，作为披露重大非公开信息的手段，并遵守FD法规规定的披露义务。。

ContactsInvestors: [email protected]Media: [email protected]

联系人投资者：[受电子邮件保护]媒体：[受电子邮件保护]

SOURCE 10x Genomics, Inc

来源10x Genomics，Inc